Oramed Pharmaceuticals (Oramed Pharmaceuticals) EV-to-FCF

Oramed Pharmaceuticals Annual Data
	Trend	Aug14	Aug15	Aug16	Aug17	Aug18	Aug19	Aug20	Aug21	Dec22	Dec23
EV-to-FCF							-1.96	-3.42	-27.91	-11.28	1.72

Oramed Pharmaceuticals Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-FCF																-11.28	2.67	0.33	-0.30	1.72

For the Biotechnology subindustry, Oramed Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's EV-to-FCF falls into.

Oramed Pharmaceuticals EV-to-FCF Calculation

Oramed Pharmaceuticals's EV-to-FCF for today is calculated as:

Oramed Pharmaceuticals's current Enterprise Value is $-18.45 Mil.
Oramed Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals  (NAS:ORMP) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Oramed Pharmaceuticals's PE Ratio for today is calculated as:

Oramed Pharmaceuticals's share price for today is $2.33.
Oramed Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.140.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Oramed Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Oramed Pharmaceuticals (Oramed Pharmaceuticals) Business Description